Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer

@article{Narita2011OutcomeCP,
  title={Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer},
  author={Shintaro Narita and Norihiko Tsuchiya and Takeshi Yuasa and Shinya Maita and Takashi Obara and Kazuyuki Numakura and Hiroshi Tsuruta and Mitsuru Saito and Takamitsu Inoue and Yohei Horikawa and Shigeru Satoh and Tomonori Habuchi},
  journal={International Journal of Clinical Oncology},
  year={2011},
  volume={17},
  pages={204-211}
}
Docetaxel-based chemotherapy is effective in patients with castration-resistant prostate cancer (CRPC). This phase II study assessed the outcome and predictive factors for prognosis and toxicity following intermittent chemotherapy with docetaxel, estramustine phosphate, and carboplatin (DEC) in patients with CRPC. Thirty-five patients were treated with a DEC regimen that consisted of a 28-day cycle of drugs as follows: docetaxel (60 mg/m2 on day 1), carboplatin (AUC 5 on day 1) and estramustine… CONTINUE READING
6 Citations
17 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Similar Papers

Loading similar papers…